Teva Ivermectin Cream - Generic Soolantra

[Admin 0]

Now there is news that Teva has released a generic version of Soolantra. According to OptumRx, "Teva launched an AB-rated generic version of Galderma’s Soolantra (ivermectin) cream." There was a reported court case about this. According to Lexology Teva prevailed. Law360 wrote "Teva Beats Nestle Unit's Suit Over Rosacea Cream Patents." 

Apparently this generic version of Soolantra has been through some hoops with several press releases about this since January 30, 2018. There appears have been a lot of litigation going on that further complicates this. You can review these press releases below with regard to Perrigo and Sol-Gel.    

A generic Soolantra is now available. For more information. 

PDF of the press release downloaded July 5, 2018:
Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1% - Jan 30, 2018.pdf

[Admin 0]

"Bayer AG BAYRY is suing it over a generic rosacea product [Finacea Foam?] after Perrigo filed for Food and Drug Administration approval for it. Bayer makes the branded product, Finacea Foam, which is approved for the raised spots and pimple-like bumps that are symptoms of mild to moderate rosacea."

Perrigo shares decline 1% on news of Bayer lawsuit over generic rosacea product, Marketwatch

Cision, on Jan 30, 2018, states, "Annual market sales for the last 12 months were approximately $120 million, according to IMS Health."
Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1%, Cision

[Admin 0]

In inquiry on the status of Perrigo's generic ivermectin cream provided a response from Bradley Joseph, VP, Global Investor Relations and Corporate Communications, Perrigo Company, who wrote, "No change in the status of this product.  We will announce via press release the launch of this product.  Thanks." 

[Admin 0]

Update

“Sol-Gel anticipates that building a portfolio of generic product candidates with favorable commercial agreements can supplement its branded pipeline and potentially have a meaningful contribution to the Company’s operating income,” stated Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “This strategy first came to fruition last January when Perrigo received tentative approval from the FDA for ivermectin cream, 1%, developed in collaboration with Sol-Gel.  Perrigo was second to file and, as of today, has the only reported tentative approval for ivermectin cream, 1%, and there is no public disclosure of a third filer to the FDA," added Dr. Seri-Levy."

Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo, Globe Newswire

[Admin 0]

 

Sol-Gel Technologies LTD is continuing its clinical trial with its generic ivermectin cream and has also released information on Epsolay for papulopustular rosacea, which is the first micro-encapsulated single active benzoyl peroxide (5%)  prescription drug. For more information or download here: 

0001178913-19-000060.pdf

[Admin 0]

Teva 1% Ivermectin Cream